Altering Chemosensitivity by Modulating Translation Elongation
Open accessThe DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The process of translation occurs at a nexus point downstream of a number of signal pathways and developmental processes. Modeling activation of the PTEN/AKT/mTOR pathway in the Emu-Myc mouse is a valuable tool to study tumor genotype/chemosensitivity relationships in vivo. In this model, blocking translation initiation with silvestrol, an inhibitor of the ribosome recruitment step has been showed to modulate the sensitivity of the tumors to the effect of standard chemotherapy. However, inhibitors of translation elongation have been tested as potential anti-cancer therapeutic agents in vitro, but have not been extensively tested in genetically well-defined mouse tumor models or for potential synergy with standard of care agents. METHODOLOGY/PRINCIPAL FINDINGS: Here, we chose four structurally different chemical inhibitors of translation elongation: homoharringtonine, bruceantin, didemnin B and cycloheximide, and tested their ability to alter the chemoresistance of Emu-myc lymphomas harbouring lesions in Pten, Tsc2, Bcl-2, or eIF4E. We show that in some genetic settings, translation elongation inhibitors are able to synergize with doxorubicin by reinstating an apoptotic program in tumor cells. We attribute this effect to a reduction in levels of pro-oncogenic or pro-survival proteins having short half-lives, like Mcl-1, cyclin D1 or c-Myc. Using lymphomas cells grown ex vivo we reproduced the synergy observed in mice between chemotherapy and elongation inhibition and show that this is reversed by blocking protein degradation with a proteasome inhibitor. CONCLUSION/SIGNIFICANCE: Our results indicate that depleting short-lived pro-survival factors by inhibiting their synthesis could achieve a therapeutic response in tumors harboring PTEN/AKT/mTOR pathway mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This effect likely occurs because harringtonine binds to free 60s subunits, but not those that are joined into an 80s ribosome. Thus, elongating ribosomes are immune to harringtonine, whereas a 60s subunit bound by harringtonine will form an 80s at a start site that does not move forward”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Robert et al., 2009
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Median effect analysis indicated a combination index (CI) below 1 for Dxr+HHT and Rap+Dxr indicative of synergy [40] (Fig 7B).”
BackgroundUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 1×
“40S ribosome (and associated factors) [7].”
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169 · cited 3×
“oncogenes may be too narrow an approach for drug development, but rather targeting nodes that reside downstream of these pathways may offer broader acting therapies [1,2].”
BackgroundThe Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833 · cited 3×
“oncogenes may be too narrow an approach for drug development, but rather targeting nodes that reside downstream of these pathways may offer broader acting therapies [1,2].”
BackgroundRock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · cited 1×
“some-inhibitor MG132 [38].”
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“Several of the proteins that play important regulatory roles in cancer progression and apoptosis have short half-lives (e.g. cyclin D1 (∼25 min)”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446 · cited 1×
“S1), as well as identified as genotype-selective antitumor agents in synthetic lethal screens [41].”
BackgroundTranslational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188 · cited 1×
“and c-Myc controls the expression of genes involved in many aspects of cell growth including cell cycle progression and survival”
Background
Research works printed but not linked: 2
- H-G Wendel, 2004, Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy., Nature, 428, 332, 10.1038/nature02369 · DOI · Paper page
- JR Mills, 2008, mTORC1 promotes survival through translational control of Mcl-1., Proc Natl Acad Sci U S A, 105, 10853, 10.1073/pnas.0804821105 · DOI · Paper page
Cited by
Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.10.002 · Cited by 2,187
“We first stopped new translation using harringtonine, which effectively blocks initiation by inhibiting elongation during the first rounds of peptide bond formation following subunit joining (Fresno et al., 1977; Robert et al., 2009).”
MethodInfluentialIngolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.086 · Cited by 1,259
Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin
Schneider-Poetsch, T., Ju, J., Eyler, D. E., Dang, Y., Bhat, S., Merrick, W. C., Green, R., Shen, B., & Liu, J. O. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.304 · Cited by 1,014
“304-annotation-312">CHX seemed to slightly stabilize the RNA species, as has been observed befor”
ResultAMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B. J., Viollet, B., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.001 · Cited by 911
“Wewould like to thank Connie Krawczyk, Arnim Pause, Jerry Pelletier, Francis Robert, David Shackelford, and Leah Donnelly for technical and administrative help.”
MethodDecoding Human Cytomegalovirus
Stern-Ginossar, N., Weisburd, B., Michalski, A., Le, V. T. K., Hein, M. Y., Huang, S.-X., Ma, M., Shen, B., Qian, S.-B., Hengel, H., et al. (2012) · Science · doi:10.1126/science.1227919 · Cited by 589
Metadata
- Authors
- Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J.
- Affiliations
- McGill University (CA)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Pelletier, Jerry
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-05-01
- Volume
- 4
- Issue
- 5
- Pages
- e5428
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2671598
- OpenAlex
- W2012346470
- Cited by
- 90
- References
- 67
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 8 · 2013: 13 · 2012: 12
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Canadian Institutes of Health Research (79385_1)
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- chemosensitivity, chemoresistance, Eμ-Myc lymphoma, homoharringtonine, bruceantin, didemnin B, cycloheximide, doxorubicin synergy, apoptosis, Mcl-1, cyclin D1, c-Myc, eIF4E, TSC2, proteasome inhibition, ribosome recruitment
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Homoharringtonine, Animals, Base Sequence, Cycloheximide, Female, Harringtonines, Lymphoma, Mice, Inbred C57BL, Mutation, Peptide Chain Elongation, Translational, Genes, myc, Proto-Oncogene Proteins c-myc, DNA Primers, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Genes, bcl-2, Cyclin D1, Tumor Suppressor Proteins, Quassins, Eukaryotic Initiation Factor-4E, Cell Line, Tumor, Depsipeptides, PTEN Phosphohydrolase, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Altering Chemosensitivity by Modulating Translation Elongation. https://app.cochat.ai/papers/10.1371/journal.pone.0005428
- The paper
- Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J. (2009). Altering Chemosensitivity by Modulating Translation Elongation. PLoS ONE. https://doi.org/10.1371/journal.pone.0005428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.